Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01082081 · ClinicalTrials.gov registry record · Phase 4
Post-operative Dental Pain Study Comparing Analgesic Efficacy
A Phase 4 study of Post-surgical Dental Pain, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
- 2
- Study locations
NCT01082081 is a Phase 4 study of Post-surgical Dental Pain that has completed, run by GlaxoSmithKline. The registered enrollment target is 300 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT01082081, a Phase 4 study of Post-surgical Dental Pain, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
- 2
- Study locations
Study Summary
GlaxoSmithKline will be conducting this trial to compare analgesics efficacy of paracetamol 1000mg vs 500mg . The post-surgical dental pain model will be used to evaluate the analgesic efficacy of paracetamol. Each subject will be enrolled in the study for up to six weeks. The duration of the entire study will be approximately 16 weeks. Each subject will have to come to the clinic for three visits (Screening, Treatment and Follow up visits).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Paracetamol 500 mg
- DRUG Paracetamol 1000 mg
Study Locations (2)
Texas
- PPD Dental Clinic - Austin
Utah
- Jean Brown Research - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01082081
The ClinicalTrials.gov registry entry for NCT01082081 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post-surgical Dental Pain appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01082081 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT01082081 about?
NCT01082081 is a clinical study titled "Post-operative Dental Pain Study Comparing Analgesic Efficacy". GlaxoSmithKline will be conducting this trial to compare analgesics efficacy of paracetamol 1000mg vs 500mg . The post-surgical dental pain model will be used to evaluate the analgesic efficacy of paracetamol. Each subject will be enrolled in the study for up to six weeks. The duration of the entire...
What is the current status of trial NCT01082081?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2009-10. Estimated completion is 2010-03.
What conditions does trial NCT01082081 study?
This clinical trial studies the following conditions: Post-surgical Dental Pain.
What interventions are being tested in trial NCT01082081?
The interventions under investigation include: Placebo (DRUG), Paracetamol 500 mg (DRUG), Paracetamol 1000 mg (DRUG).
Who is sponsoring clinical trial NCT01082081?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01082081 being conducted?
This trial has 2 study locations across Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.